Genprex Collaborators Report Positive TUSC2 and Checkpoint Blockade Preclinical Data at the 2019 AACR Annual Meeting
April 08 2019 - 8:30AM
Business Wire
TUSC2 Immunogene Therapy Overcomes Resistance
to Checkpoint Blockade
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy
company, reported that its collaborators from The University of
Texas MD Anderson Cancer Center (“MD Anderson”) presented positive
preclinical data for the combination of the TUSC2 gene with an
anti-PD1 antibody, pembrolizumab, for the treatment of lung cancer
in a poster presented at the American Association of Cancer
Research Meeting 2019. The TUSC2 gene is a tumor suppressor gene,
the active agent in Genprex’s Oncoprex™ immunogene therapy.
The poster, entitled “Development of an improved humanized
patient-derived xenograft, Hu-PDX, mouse model for evaluation of
antitumor immune response in lung cancer” showed that TUSC2
combined with checkpoint blockade was more effective than
checkpoint blockade alone in increasing the survival of mice with
human immune cells (humanized mice) that had metastatic lung
cancer. The TUSC2 treatment with the checkpoint inhibitor
pembrolizumab slowed tumor growth significantly. Pembrolizumab
previously had no effect on tumor growth in non-humanized mice. The
data also demonstrated the Hu-PDX model as an improved platform for
evaluation of immunotherapy.
“This sophisticated model gets one step closer to recapitulating
certain functions of the human immune response within a manageable
scientific animal model and allows us to further test our
hypotheses of how a more complex immune system could interact with
aggressive cancers when primed by drugs, such as Oncoprex, in
humans,” said Julien L. Pham, MD, MPH, President and Chief
Operating Officer of Genprex. “These data further support and
solidify existing preclinical data showing that Oncoprex immunogene
therapy is synergistic with anti-PD1 therapy and could result in a
stronger antitumor response compared to either agent alone. It also
demonstrates how Oncoprex could be used in combination with other
immunotherapies as a viable treatment option for late-stage
non-small cell lung cancer.”
Poster Presentation Details:
Date/Time: Wednesday, April 3, 2019 from 8 a.m. to 12
p.m. ETLocation: Georgia World Congress Center, Exhibit Hall
BSession: Immunomodulators and Response to
TherapyTitle: Development of an improved humanized
patient-derived xenograft, Hu-PDX, mouse model for evaluation of
antitumor immune response in lung cancerAuthors: Ismail M.
Meraz, Mourad Majidi, Feng Meng, RuPing Shao, Min Jin Ha, Shinya
Neri, Bingliang Fang, Steven H. Lin, Peggy T. Tinkey, Elizabeth J.
Shpall, Jeffrey Morris, Jack A. Roth. UT MD Anderson Cancer Ctr.,
Houston, TX
Following the AACR annual meeting, the poster will also be made
available on Genprex’s website at genprex.com.
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing potentially life-changing technologies for cancer
patients, based upon a unique proprietary technology platform,
including Genprex’s initial product candidate, Oncoprex™ immunogene
therapy for non-small cell lung cancer (NSCLC). Genprex’s platform
technologies are designed to administer cancer fighting genes by
encapsulating them into nanoscale hollow spheres called
nanovesicles, which are then administered intravenously and taken
up by tumor cells where they express proteins that are missing or
found in low quantities. Oncoprex has a multimodal mechanism of
action whereby it interrupts cell signaling pathways that cause
replication and proliferation of cancer cells, re-establishes
pathways for apoptosis, or programmed cell death, in cancer cells,
and modulates the immune response against cancer cells. Oncoprex
has also been shown to block mechanisms that create drug
resistance. Visit the company’s web site at www.genprex.com or
follow Genprex on Twitter at twitter.com/genprex, Facebook at
facebook.com/genprexinc, and LinkedIn at
linkedin.com/company/genprex.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effects of Oncoprex, or Oncoprex in combination with
immunotherapies, on cancer. Risks and uncertainties associated with
Genprex and its lead product candidate Oncoprex are described more
fully under the caption "Risk Factors" and elsewhere in our filings
and reports with the United States Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. We
undertake no obligation to update such statements to reflect events
that occur or circumstances that exist after the date on which they
were made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190408005231/en/
Genprex, Inc.(877) 774-GNPX (4679)
Investor RelationsGNPX Investor Relations(877) 774-GNPX
(4679) ext. #2investors@genprex.com
Media ContactGenprex Media RelationsKalyn Dabbs(877)
774-GNPX (4679) ext. #3media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2023 to Apr 2024